EGFR inhibitors provide benefit in patients with advanced and metastatic head and neck squamous cell carcinoma (HNSCC). Mass spectrometry profiling has been used to predict outcome in patients with HNSCC after EGFR inhibitor treatment, and may enable prior identification of patients most likely to benefit from these therapies. However, further validation in prospective studies is needed.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Taguchi, F. et al. Mass spectrometry to classify non-small cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross institutional study. J. Natl Cancer Inst. 99, 838–846 (2007).
Carbone, D. P. et al. VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer doi: 10.1016/j.lungcan.2009.11.019
Amann, J. M. et al. Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503. J. Thorac. Oncol. 5, 169–178 (2010).
Salmon, S. et al. Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen. J. Thorac. Oncol. 4, 689−696 (2009).
Chung, C. H. et al. Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. Cancer Epidemiol. Biomarkers Prev. 19, 358–365 (2010).
Ocak, S., Chaurand, P. & Massion, P. P. Mass spectrometry-based profiling of lung cancer. Proc. Am. Thorac. Soc. 6, 159–170 (2009).
Diamandis, E. P. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J. Natl Cancer Inst. 96, 353–356 (2004).
Bernier, J., Bentzen, S. M. & Vermorken, J. B. Molecular therapy in head and neck oncology. Nat. Rev. Clin. Oncol. 6, 266–277 (2009).
Cooper, J. B. & Cohen, E. E. Mechanisms of resistance to EGFR inhibitors in head and neck cancer. Head Neck 31, 1086–1094 (2009).
Govindan, R. INTERESTing biomarker to select IDEAL patients for epidermal growth factor receptor tyrosine kinase inhibitors: Yes, for EGFR mutation analysis, Others, I PASS. J. Clin. Oncol. 28, 713–715 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Ang, MK., Hayes, D. Mass spectrometry in HNSCC—a peek at response prediction?. Nat Rev Clin Oncol 7, 193–195 (2010). https://doi.org/10.1038/nrclinonc.2010.35
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2010.35
